Cargando…
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on pegfilgrastim-associated bone pain. METHODS: In this open-label study (NCT01712009), women ≥ 18 ...
Autores principales: | Kirshner, Jeffrey J., McDonald, Maxwell C., Kruter, Flavio, Guinigundo, Andrew S., Vanni, Linda, Maxwell, Cathy L., Reiner, Maureen, Upchurch, Terry E., Garcia, Jacob, Morrow, Phuong Khanh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847062/ https://www.ncbi.nlm.nih.gov/pubmed/29147854 http://dx.doi.org/10.1007/s00520-017-3959-2 |
Ejemplares similares
-
Lt. Martin F. Nolan
Publicado: (1918) -
The HLA diversity of the Anthony Nolan register
por: Leen, Gayle, et al.
Publicado: (2020) -
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2020) -
A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021) -
COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)